La vendita allo scoperto per Esperion Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Esperion Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Esperion Therapeutics (NASDAQ:ESPR) Azioni, Report sulle vendite allo scoperto

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HOLDINS LTD by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

WIIM

ESPR

Esperion Therapeutics shares are trading higher after the company announced that its European partner, Daiichi Sankyo Europe, reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study –
– Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe –
– Data From the MILOS German Cohort Showed Bempedoic Acid, Alone or With Ezetimibe, Was Effective and Had A Safety Profile in Real-World Settings Consistent With the CLEAR Outcomes Study –
ANN ARBOR, Mich., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that its European partner, Daiichi Sankyo Europe (DSE), reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study. The European study evaluated the real-world use of bempedoic acid, marketed as NILEMDO&#xAE;&nbsp;in the EU and bempedoic acid and ezetimibe, marketed as NUSTENDI&#xAE; in the EU, in patients with primary hypercholesterolemia or mixed dyslipidemia. The products are marketed as NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE;&nbsp;(bempedoic acid and ezetimibe) in the U.S.
The results, presented in Hamburg, Germany at DGK Herztage 2024, demonstrated the effectiveness and safety profile of bempedoic acid, both alone and in combination with other lipid-lowering therapies (LLTs) in clinical practice. Raised LDL-C is a key modifiable contributor to risk of major cardiovascular events, with studies showing that every 1 mmol/L reduction in LDL-C is associated with a 22% reduction in major cardiovascular events after one year.
The German cohort of the MILOS study comprising 973 patients from 125 sites in Germany, is one of the most comprehensive assessments of bempedoic acid in a real-world clinical setting to-date in Germany.&nbsp;Patients were followed-up for two years, with LDL-C levels assessed at pre-treatment, one year (1Y) and two years (2Y). Overall, 638 of 973 patients (65.6%) completed 2Y follow up, with LDL-C values at pre-treatment, 1Y and 2Y available for 451 patients. In these 451 patients, a mean reduction of LDL-C levels from 3.1 mmol/L (121.4 mg/dL) at pre-treatment, to 2.0 mmol/L (77.2 mg/dL) was observed, representing an average relative reduction of 30.3% in the overall population.
Additionally, the percentage of patients reaching their LDL-C goals increased from 4.9% at pre-treatment to 35.3% at the 2Y follow-up – an approximately 7-fold increase.&nbsp;The proportions of high-risk and very high-risk patients reaching LDL-C goals increased from 5.6% to 32.5%, and 3.6% to 35.2%, respectively.
Overall, more than 80% of patients received bempedoic acid in combination with other LLTs at pre-treatment and 2Y, including statins and ezetimibe. The safety profile of bempedoic acid in this real-world population was assessed at 1Y and 2Y and was consistent with that observed in the CLEAR clinical trial program.&nbsp;

Biotech

General

Esperion EU Partner Reports Final Real-World Results From MILOS German Cohort Demonstrating Strong Increase In LDL-C Goal Achievement With Addition Of Bempedoic Acid

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – &nbsp;
– Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers –
– NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Both Primary and Secondary Prevention Patients –
ANN ARBOR, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Esperion today announced that NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration's (FDA) approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives (92% of all commercial lives) and 34 million Medicare lives (65% of all Medicare lives). Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.
 &nbsp;

Esperion Secures Additional Commercial And Medicare Formulary Coverage For NEXLETOL And NEXLIZET; New Additions To Medicare Formularies At Optum/United AARP And CVS/SilverScript Coupled With Humana Provides Access To More Than 65% Of Medicare Insured Lives And More Than 92% Of Commercially Insured Lives

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and lowers the price target from $8 to $6.

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $6

Shares of Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) rose sharply in today's pre-market trading after the company announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology.
Ainos shares jumped 37.7% to $0.7200 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 49% to $0.3201 in today's pre-market trading. On Aug. 5, LogicMark announced the closing of $4.5 million public offering priced at-the-market.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) gained 27.7% to $1.29 in pre-market trading after jumping 46% on Friday.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares rose 27.3% to $14.28 in pre-market trading.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 24.5% to $0.2490 in pre-market trading. FSD Pharma shares jumped 118% on Friday after Celly Nutrition, which is backed by FSD Pharma, announced the upcoming launch of its &#8216;unbuzzd&#8217; recovery drink.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) gained 18.5% to $0.16. Genius Group shares gained around 8% on Friday after the company announced its board approved the purchase of up to 10 million shares by founder and CEO Roger James Hamilton.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) gained 15.4% to $1.41 in pre-market trading. The company, last week, posted a narrower-than-expected quarterly loss.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) jumped 12.8% to $1.12 in pre-market trading.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 11.4% to $2.25 in pre-market trading.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares gained 10.1% to $0.2999 in pre-market trading after declining around 20% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) shares declined 27.7% to $0.6810 in pre-market trading. Meta Materials shares dipped around 55% on Friday after the company disclosed in an SEC filing that it ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 in the US Bankruptcy Court.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dipped 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) declined 16.9% to $0.49 in pre-market trading. Tenon Medical will release financial results for the second quarter after the closing bell on Aug. 13.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined 15.4% to $0.21 in pre-market trading. Sonoma Pharmaceuticals shares dipped around 20% on Friday after the company reported worse-than-expected first-quarter financial results.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 13.4% to $6.85 in pre-market trading after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.</li>
<li>Big Tree Cloud Holdings Limited  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares fell 11.6% to $1.30 in pre-market trading after jumping 70% on Friday.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) fell 11.1% to $0.0448 in pre-market trading. ENDRA Life Sciences will report financial results for the three and six months ended June 30 on Wednesday, Aug. 14.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) fell 7.7% to $4.19 in today's pre-market trading after the company reported worse-than-expected second-quarter results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) fell 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AILE

AIMD

ANTE

CMAX

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

LGMK

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Earnings

Guidance

Health Care

Esperion Reiterates Its Full Year 2024 Operating Expense Guidance Of Approximately $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

Esperion Therapeutics Q2 2024 GAAP EPS $(0.33) Misses $(0.18) Estimate, Sales $73.834M May Not Be Comparable To $49.056M Estimate

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $8 price target.

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

Esperion Therapeutics shares are trading lower after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher, but it has since reversed.

Esperion Therapeutics shares are trading higher after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences.

Esperion Says It Enters Into A Royalty Purchase Deal With Omers Life Sciences, Under Which It Got $304.7M In Exchange For 100% Interest In Esperion's Royalty Entitlement On Daiichi Sankyo Europe's Net Sales Of Bempedoic Acid Products In Europe

Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) fell sharply during Thursday's session <a href="https://www.benzinga.com/news/earnings/24/06/39411910/jabil-tops-q3-estimates-ceo-highlights-strategic-growth-in-ai-datacenters-and-ev-markets">following third-quarter results</a>.
Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22).
Jabil shares dipped 7.8% to $116.37 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares jumped 222.8% to $1.48 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.</li>
<li>Griid Infrastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRDI#NASDAQ">GRDI</a>) climbed 89.3% to $1.48 after falling more than 10% on Tuesday.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 89% to $2.58 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending September 30, 2025.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) shares climbed 60.5% to $0.6279. Reliance Global Group announced major enhancement of capital structure following cashless exercise of warrants.</li>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 50% to $1.598. Allurion announced publication of new data demonstrating lean mass gains in patients experiencing 14% weight loss.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) rose 43% to $0.1702 after jumping 19% on Tuesday.</li>
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) gained 23.3% to $5.96.</li>
<li>Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) rose 22% to $1.1650 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 21.1% to $9.63 after gaining 9% on Tuesday.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) jumped 20.6% to $0.3850.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) gained 20.2% to $3.75.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) surged 19.7% to $1.1303. MicroCloud Hologram entered into convertible note purchase agreements with investors for $28 million on June 18.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares climbed 19.2% to $0.0877after falling around 5% on Tuesday.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) gained 16.5% to $1.91. Nanoviricides reported that the ultra-broad-spectrum antiviral NV-387, a Phase 2 Stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected influenza H3N2 mouse model.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) rose 16.4% to $2.47.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) jumped 15.3% to $5.95.</li>
<li>Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) climbed 13.7% to $6.49.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) gained 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) rose 11.4% to $3.92</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 11.3% to $12.91.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) jumped 11.1% to $8.23</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) surged 11% to $0.5849</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) gained 10% to $1.1450. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on &#8216;Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.&#8217;</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares climbed 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) rose 5% to $162.36.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 43.7% to $0.1993. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.</li>
<li>Kaival Brands Innovations Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares declined 33.5% to $2.99 after gaining 8% on Tuesday.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) fell 29% to $1.10. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.</li>
<li>Tempest Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) declined 25% to $2.1208. The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).</li>
<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) declined 23.6% to $0.3672. Nikola announced 1-for-30 reverse stock split approved by board.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares fell 23.5% to $1.37. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.</li>
<li>SYLA Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYT#NASDAQ">SYT</a>) dipped 21.7% to $1.70.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares dipped 21% to $0.6721 after the company announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 20.9% to $72.55.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) tumbled 20.3% to $0.1910 after jumping 82% on Tuesday.</li>
<li>DermTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) fell 19.4% to $0.1176.</li>
<li>Dunxin Financial Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NASDAQ">DXF</a>) shares fell 19.4% to $0.1728 after dipping 17% on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) fell 15.1% to $25.76 amid post-IPO volatility.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) declined 15% to $2.2991 after B of A Securities downgraded the stock from Neutral to Underperform.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 13.7% to $0.2150. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) fell 12.2% to $1.8602. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft&#8217;s public sector distributor.</li>
<li>Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) declined 10.1% to $20.84. Jasper Therapeutics announced appointment of Svetlana Lucas Ph.D., to its Board of Directors.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) declined 6.5% to $84.02 after the company reported mixed fourth-quarter financial results.</li>
<li>Nayax Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) fell 6.1% to $21.23.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) fell 5% to $6.03 after the company&#8217;s board determined that recent takeover proposals were not in its best interests.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39411935/this-skyworks-solutions-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday">This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday</a>

Intraday Update

ALUR

APLD

ASNS

BILI

DMTK

FEMY

GRDI

HIMX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

IBRX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KAVL

LOBO

LRHC

MBIO

MGOL

MOLN

NKLA

NLSP

NNVC

NYAX

OCUL

PACK

PRST

RELI

SLNH

SMCI

SONN

SRFM

SVMH

TBLT

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

VNDA

ZAPP

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Esperion Therapeutics shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised the price target for Bread Financial Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) from $42 to $45. Evercore ISI Group analyst John Pancari upgraded the stock from Underperform to In-Line. Bread Financial shares gained 0.5% to close at $40.84 on Tuesday. <a href="https://www.benzinga.com/quote/BFH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised the price target for Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) from $7 to $11. TD Cowen analyst Tara Bancroft upgraded the stock from Hold to Buy. Ocular Therapeutix shares fell 0.2% to close at $5.49 on Tuesday. <a href="https://www.benzinga.com/quote/OCUL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group increased KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) price target from $78 to $86. Evercore ISI Group analyst Stephen Kim maintained an Outperform rating. KB Home shares fell 2.1% to close at $68.04 on Tuesday. <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut the price target for Shattuck Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) from $28 to $16. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Shattuck Labs shares fell 7.8% to close at $4.59 on Tuesday. <a href="https://www.benzinga.com/quote/SSTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities slashed Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) price target from $2.9 to $2.5. B of A Securities analyst Jason Zemansky downgraded the stock from Neutral to Underperform. Esperion Therapeutics shares fell 5.2% to close at $2.72 on Tuesday. <a href="https://www.benzinga.com/quote/ESPR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $277 to $316. Baird analyst Mark Marcon maintained an Outperform rating. Workday shares fell 2.2% to close at $207.69 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein boosted the price target for Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) from $150 to $200. Bernstein analyst Mark Li maintained an Outperform rating. Taiwan Semiconductor Manufacturing shares gained 1.4% to close at $179.69 on Tuesday. <a href="https://www.benzinga.com/quote/TSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $475 to $540. Keybanc analyst Justin Patterson maintained an Overweight rating. Meta Platforms shares fell 1.4% to close at $499.49 on Tuesday. <a href="https://www.benzinga.com/quote/META/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) price target from $66 to $69. Keefe, Bruyette &amp; Woods analyst David Konrad maintained a Market Perform rating. Citigroup shares gained 1.2% to close at $60.78 on Tuesday. <a href="https://www.benzinga.com/quote/C/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) price target from $160 to $187. B of A Securities analyst Christopher Nardone maintained a Buy rating. Crocs shares fell 0.2% to close at $159.42 on Tuesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/06/39405641/hewlett-packard-enterprise-accenture-and-3-stocks-to-watch-heading-into-thursday">Hewlett Packard Enterprise, Accenture And 3 Stocks To Watch Heading Into Thursday</a>

CROX

STTK

WDAY

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

B of A Securities analyst Jason Zemansky downgrades Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) from Neutral to Underperform and lowers the price target from $2.9 to $2.5.

Downgrades

B of A Securities Downgrades Esperion Therapeutics to Underperform, Lowers Price Target to $2.5

Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has <a href="https://www.benzinga.com/quote/SKYE/news">discontinued the program</a>.
Skye Bioscience shares tumbled 18.9% to $8.87 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares jumped 123% to $4.3001 following the completion of the company&#8217;s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 79.8% to $0.7082 after the company was awarded a sub-contract worth up to C$48 million by Thales Canada for software development services.</li>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) jumped 63% to $0.5547. Wearable Devices reported the successful completion of its first phase of integration with Qualcomm&#8217;s Snapdragon Spaces&#x2122;, extended reality (XR) Developer Platform.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) gained 45.1% to $1.0450 after declining around 8% on Friday.</li>
<li>ICC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCH#NASDAQ">ICCH</a>) jumped 43% to $22.03. Mutual Capital Group announced plans to acquire ICC Holdings, Inc. for $23.50 per share in a $73.8 million transaction.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) shares gained 32.3% to $0.5623 after jumping over 15% on Friday.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 28.6% to $283.00.</li>
<li>Renovaro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) rose 25.6% to $1.62.</li>
<li>Wetouch Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) surged 25% to $2.23.</li>
<li>Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) gained 24% to $5.83.</li>
<li>Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) surged 22% to $16.83.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) rose 20.2% to $5.33.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) gained 18% to $10.74.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) jumped 17.5% to $5.58.</li>
<li>Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) surged 17% to $2.62.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) jumped 16.6% to $0.4960 after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) gained 15% to $0.1070 after the company was awarded a new US patent titled &#8216;Automated Growing Systems.&#8217;</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 13.6% to $0.9869. FuelCell Energy reported a second-quarter fiscal 2024 revenue decline of 42% year-over-year to $22.42 million, beating the consensus of $21.35 million.</li>
<li>Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) gained 13.6% to $53.19.</li>
<li>Tellurian Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NASDAQ">TELL</a>) gained 12.8% to $0.8448.</li>
<li>SEACOR Marine Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) gained 12.1% to $13.26.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares rose 10.9% to $0.0988 after surging 17% on Friday.</li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) gained 9.8% to $107.63 after it was announced the company will join the S&amp;P 500.</li>
<li>Diamond Offshore Drilling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DO#NYSE">DO</a>) climbed 9.8% to $15.30 after Noble announced an agreement to acquire the company.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) gained 8.8% to $379.95 after it was announced the company will join the S&amp;P 500.</li>
<li>LENZ Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) rose 8.2% to $16.85.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) shares rose 7.6% to $3.6302 after the company said it has established a daily supply capacity of over 20 million eggs.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 7.5% to $3.01.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) gained 6.8% to $29.66 following a report indicating Elliott Investment Management has built a stake in the company.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) rose 5.9% to $4.8592. Barclays initiated coverage on Geron with an Overweight rating and announced a price target of $9.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) dipped 32.5% to $0.4828.</li>
<li>Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) fell 32% to $3.7001</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares fell 31.4% to $0.3830.</li>
<li>Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) dipped 30% to $3.6051</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) fell 29.3% to $2.3550. Tonix Pharmaceuticals recently announced a 1-for-32 reverse stock split.</li>
<li>Enservco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENSV#NYSE">ENSV</a>) fell 29.3% to $0.1713 after the company announced the staff of NYSE Regulation determined to commence proceedings to delist its common stock.</li>
<li>Perion Network Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) shares fell 28.3% to $8.84 after the company cut its revenue outlook.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 24.7% to $0.6249 after the company announced the voluntary delisting date of its ADS rights from Nasdaq.</li>
<li>SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) declined 23% to $4.22.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 19.9% to $19.62</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 16.8% to $2.66 in pre-market trading after jumping 58% on Friday.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares fell 14.8% to $1.68.</li>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) fell 14.7% to $0.1498 after jumping 45% on Friday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 13.1% to $24.53. On Friday, the stock traded lower as Roaring Kitty held a live stream and the company reported Q1 earnings.</li>
<li>Golden Matrix Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMGI#NASDAQ">GMGI</a>) declined 12.5% to $3.16.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 11.8% to $16.01.</li>
<li>Anywhere Real Estate Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) fell 10.6% to $3.4150.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 10.6% to $10.11</li>
<li>BioCardia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares fell 10% to $3.35. On Friday, BioCardia announced it received approval from the United States Patent Office for its application entitled, "Radial and Transendocardial Delivery Catheter."</li>
<li>Cumulus Media Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares fell 7.6% to $2.9550 after jumping around 22% on Friday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) fell 7.6% to $12.36. Compass Minerals International named Jeffrey Cathey as its new chief financial officer.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) fell 7% to $68.08.</li>
<li>Roma Green Finance Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined 6% to $0.4683. Roma Green Finance filed for offering in a best efforts self-underwritten offering of up to 3.6 million of ordinary shares.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39249956/flexshopper-and-3-other-stocks-under-5-insiders-are-buying">FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying</a>

AGRI

BCDA

CELH

CLEU

CMLS

CRWD

DERM

EFSH

ENSV

FCEL

GERN

GMGI

HOUS

HOVR

ICCH

LENZ

MLGO

NISN

NVAX

OPRA

PERI

RENB

ROMA

SBFM

SIFY

SKYE

SMHI

SPEC

SYNX

TELL

THAR

TNXP

TPHS

VRAX

WETH

WLDS

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/AGX/earnings">first-quarter financial results</a>.
Argan posted quarterly earnings of 58 cents per share, beating market estimates of 52 cents per share. The company's quarterly sales came in at $157.68 million versus expectations of $134.75 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Argan shares climbed 11.1% to $76.78 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares climbed 26% to $4.90 as the company reported the FDA approval of RYTELO&#x2122; (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares jumped 18.8% to $4.11.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) rose 18.3% to $43.49 after the company approved a share buyback and raised its Q2 guidance.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) climbed 14.7% to $5.42. Yext is said to hire investment bankers to explore strategic alternatives, including a sale, Reuters reported.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) climbed 9.6% to $1.9950 following better-than-expected quarterly earnings.</li>
<li>Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) gained 9.4% to $22.27 as the company reported financial results for the second quarter ended April 30, 2024.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 8.7% to $2.6850.</li>
<li>Waldencast plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) rose 8.6% to $4.77.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) climbed 8.5% to $2.17.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 7.8% to $39.57. B. Riley Securities analyst Hal Goetsch initiated coverage on Dave with a Buy rating and announced a price target of $60.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 7.6% to $29.48.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) gained 7.2% to $27.72.</li>
<li>Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) gained 4.2% to $38.32 following better-than-expected first-quarter earnings.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 3.7% to $108.49.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39227364/this-exxon-mobil-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday">This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a>

BRZE

CRDO

CVNA

DAVE

LMNR

MBLY

NWTN

SPWR

WALD

YEXT

Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Esperion Therapeutics: Strategically Positioned To Grow

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Esperion (ESPR – Research Report), with a price target of $...

Market Outperform: Enhanced Insurance Coverage and FDA Approvals Propel Esperion's Growth Potential

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $16.00. Josep...

Esperion's Clinical and Financial Advancements Solidify Buy Rating

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high growth. Thus, investing in fundamentally strong small-cap stocks Esperion Therapeutics (ESPR), Innoviva, Inc. (INVA), and SIGA Technologies (SIGA) could be significantly rewarding. Read on… The biotech industry plays a crucial role in advancing healthcare through innovative therapies, genetic research, and drug development. The sector is driven by the demand for therapeutic treatments and genetic disorders cures, which is gaining momentum in the market.
Amid this, it could be wise to invest in fundamentally sound small-cap biotech stocks, Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), and SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>), with game-changing potential.
The biotech sector is witnessing heightened activity with firms working on breakthrough technologies. For instance, the broader biopharma sector had a strong second quarter, <a href="https://www.bioworld.com/articles/710642-despite-q2-drop-2024-h1-biopharma-financings-near-full-year-2023?v=preview">raising $22.94 billion</a>, and its half-year 2024 results were almost equal to the full-year 2023 results of $70 million.
Further, factors like increased funding and M&amp;A activities in Q2 are also the reason for such a favorable outlook for this sector. This year, there were <a href="https://investingnews.com/biotech-forecast/">28 merger and acquisition deals</a> where large pharma companies are investing in the research and development of small-cap companies.
According to <a href="https://www.precedenceresearch.com/biotechnology-market">Precedence research</a>, the global biotechnology market is anticipated to reach a value of $4.61 trillion by 2034, exhibiting a CAGR of 11.5%. This growth promises growth and explosive returns, driving market buzz and investment interest.
With that in mind, let's evaluate the fundamentals of the featured <a href="https://stocknews.com/category/biotech/">Biotech</a> industry stocks, starting with number three:
Stock #3: Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR, a pharmaceutical company, has a <a href="https://www.investopedia.com/terms/m/marketcapitalization.asp">market cap</a> of $415.99 million, and it develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to easily prescribe it to primary and secondary prevention patients.
On May 22, ESPR and Daiichi Sankyo Europe GmbH jointly announced the approval from the European Commission (EC) for the label update of both NILEMDO and NUSTENDI. The treatment is to be used for hypercholesterolemia and to reduce the risk of adverse cardiovascular events.
For the six-month period that ended on June 30, 2024, ESPR's total revenues increased 322.2% year-over-year to $211.57 million, while the company reported net revenue of $53.06 million, indicating a 42.2% growth from the prior-year period.
Street expects ESPR's revenue for the fiscal third quarter (ended September 2024) to increase 55.7% year-over-year to $52.88 million. In addition, it surpassed the revenue estimates in each of the trailing four quarters, which is promising.
ESPR's stock has surged 153.6% over the past year to close the last trading session at $2.12.
ESPR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
ESPR has a B grade for Growth, Value, and Quality. It is ranked #35 out of 330 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ESPR/">Click here</a> to see the additional ratings for ESPR (Momentum, Stability, and Sentiment).
Stock #2: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
With a market cap of $1.26 billion, INVA develops and commercializes pharmaceutical products internationally. It has a portfolio of royalties and other healthcare assets.  The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
On May 20, INVA and Zai Lab Limited (<a href="https://stocknews.com/stock/ZLAB/">ZLAB</a>) received approval from China's National Medical Products Administration (NMPA) for XACDURO. It shall be used to treat hospital-acquired and ventilator-associated pneumonia caused by resistant Acinetobacter strains. This approval is a significant step toward combating antibiotic resistance.
In the six-month period that ended on June 30, 2024, INVA's total revenue increased 12.7% year-over-year to $177.40 million. The company's net income came in at $1.85 million or $0.03 per share for the period. INVA's cash and cash equivalents at the end of the period were $217 million, indicating 25.4% growth from the prior-year period.
Analysts expect INVA's revenue for the third quarter (ended September 2024) to increase 14.4% year-over-year to $76.91 million, while its EPS for the same period is expected to grow 47.2% from the prior year's period to $0.27. The company surpassed consensus revenue in three of the trailing four quarters, which is promising.
Over the past year, the stock has surged 50.7%, closing the last trading session at $20.21.
It's no surprise that INVA has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Value and a B for Quality. Out of 330 stocks in the same industry, INVA is ranked #31.
Beyond what is stated above, we've also rated INVA for Growth, Momentum, Stability, and Sentiment. Get all INVA ratings <a href="https://stocknews.com/stock/INVA/">here</a>.
Stock #1: SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
With a market capitalization of $485.31 million, SIGA is a commercial-stage pharmaceutical firm focused on the health security market. Its main offering is TPOXX, an oral antiviral drug intended to treat variola virus-induced smallpox in humans.
On October 8, SIGA announced an agreement to supply TPOXX (tecovirimat) in Morocco, collaborating with the Ministry of Health in Morocco. This agreement will help SIGA establish its global presence and mark its first commercial sale on the continent.
On August 21, SIGA announced that the U.S. Department of Defense (DOD) had procured approximately $9 million of TPOXX. This contract represents the third award from the DOD in the past three years.
SIGA, for the second quarter (ended June 30, 2024), reported total revenues of $21.81 million, indicating a 271% growth from the prior-year quarter, and its product sales and supportive services revenue increased significantly year-over-year to $20.68 million.
In addition, the company's net and comprehensive income stood at $1.83 million compared to the prior-year quarter's loss of $2.88 million, while its income per share came in at $0.03 versus a loss of $0.04 per share last year.
The consensus revenue estimate of $160.46 million for the fiscal year (ending December 2024) represents a 14.7% increase year-over-year. The consensus EPS estimate of $1 for the same quarter indicates a 5.1% improvement year-over-year.
The stock has gained 30.3% over the past nine months and 25% over the past year to close the last trading session at $6.80.
SIGA's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Biotech industry, it is ranked #16. <a href="https://stocknews.com/stock/SIGA/">Click here</a> to see SIGA's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
INVA shares were trading at $20.19 per share on Thursday afternoon, down $0.02 (-0.10%). Year-to-date, INVA has gained 25.87%, versus a 24.06% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/inva-siga-espr-zlab-3-small-cap-biotech-stocks-with-game-changing-potential/>3 Small-Cap Biotech Stocks With Game-Changing Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Biotech Stocks With Game-Changing Potential

In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion (ESPR – Research Report). The compa...

Bank of America Securities Keeps Their Sell Rating on Esperion (ESPR)

INVA

SIGA

ZLAB

Press Releases

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Comments

Esperion Therapeutics

Vendite allo scoperto

Esperion Therapeutics (NASDAQ:ESPR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO